Zealand Pharma A/S (0NZU.L)

126,80 +8,08 (+6,81%) In data: 05:30PM BST. Mercato aperto.

Zealand Pharma A/S

Sydmarken 11
SOeborg
Copenhagen 2860
Denmark
45 88 77 36 00
https://www.zealandpharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 253

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Adam Sinding Steensberg M.D.	President & CEO	11,89M	N/D	1974
Ms. Henriette Wennicke	EVP & CFO	4,85M	N/D	1983
Mr. Ivan Mourits Moller	Executive VP & COO	N/D	N/D	1972
Dr. David M. Kendall M.D.	Chief Medical Officer and Head of R&D	N/D	N/D	1961
Mr. Mads Kronborg	Head of Investor Relations & Communication	N/D	N/D	N/D
Mr. Ravinder Singh Chahil	EVP & General Counsel	N/D	N/D	1968
Ms. Christina Sonnenborg Bredal	Executive VP & Chief People Officer	N/D	N/D	1985
Dr. Jens Damsgaard Mikkelsen M.D.	Head of Molecular Pharmacology	N/D	N/D	N/D
Dr. Danilo Verge	Head of Global Medical Affairs	N/D	N/D	N/D
Lykke Romer	VP & Head of Finance and Accounting	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in DKK.

Descrizione

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Governance aziendale

L'ISS Governance QualityScore di Zealand Pharma A/S al 1 maggio 2024 è 3. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 1; diritti degli azionisti: 1; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.